Should I Buy Regeneron Stock in 2025? Expert Guide for Ireland

What is Regeneron?

How much is the Regeneron stock?

The price of Regeneron stock is rising this week. At present, the share trades at $605.39, showing a 2.29% increase over the last 24 hours, though it has slipped by 2.90% over the past week. The company holds a market capitalisation of $65.36 billion, with a three-month average daily volume of 1.13 million shares. Regeneron’s P/E ratio stands at 15.41, with a dividend yield of 0.58%, and the stock beta is 0.62, indicating relatively low volatility. While Regeneron’s stability may appeal to cautious investors in Ireland, recent fluctuations highlight the importance of monitoring sector developments.

Our complete analysis of the Regeneron stock

Having thoroughly analysed Regeneron Pharmaceuticals’ most recent earnings, its three-year share price trajectory, and the prevailing competitive landscape, our proprietary models integrate a wealth of financial, technical, and sectoral data to pinpoint potential opportunities. Regeneron, as a US-listed biotechnology powerhouse, emerges from a period of recalibration with robust fundamentals, a diversified pipeline, and a stream of catalysts that demand renewed attention. So, why might Regeneron stock once again become a strategic entry point into the global biotech sector in 2025?

Recent Performance and Market Context

Regeneron (NASDAQ: REGN) currently trades at $605.39 per share (as of 30 May 2025), after an intraday gain of +2.29%. The share price, while off its 52-week high of $1,211.20, now hovers just above its 52-week low of $520.50—an area historically associated with strong investor accumulation. Over the past year, Regeneron shares have adjusted by -38.24%, and are down -15.01% year-to-date, reflecting both broad sector repricing and stock-specific factors. Notably, the recent pre-market quotation of $535.00 (-11.63%) is indicative of potential technical volatility, providing dynamic entry points for strategic investors.

Yet, beneath these headline moves lies a series of constructive developments:

• Resilient revenue growth: Q4 2024 revenues increased by +10% year-on-year, with full-year 2024 revenues reaching $14.2 billion (+8% vs 2023).
• Product momentum: Dupixent and EYLEA HD continue to drive top-line expansion, supported by recent FDA approvals and new indications.
• Shareholder returns: Initiation of a quarterly dividend ($0.88/share) and a $4.5 billion expansion of the share repurchase programme reinforce capital discipline.
• Strategic M&A and manufacturing partnerships: The acquisition of 23andMe and a $7 billion manufacturing investment with FUJIFILM Diosynth signal confidence in scalable growth.

In a broader context, the pharmaceutical and biotech sectors remain in favour given their structural defensive characteristics, ongoing innovation cycles, and resilience to shifting interest rate regimes. For Irish and European investors, Regeneron thus provides diversified US-dollar exposure within a sector increasingly prioritised for healthcare systems globally.

Technical Analysis

Regeneron’s technical profile in late May 2025 reveals a compelling confluence of signals:

• Relative Strength Index (RSI 14d): 54.15 (neutral), pointing to neither overbought nor oversold conditions—a fertile ground for trend acceleration.
• MACD (12,26,9): 2.51 (mild sell signal), though this should be interpreted within the context of strong underlying support.
• Moving Averages: The share trades above its 20-day ($584.26) and 50-day ($593.71) moving averages (both generate buy signals), while longer averages (100d: $643.25, 200d: $793.07) remain laggard due to the post-rally correction; this structure is frequently associated with nascent bullish reversals.
• Support & Resistance: Key support at $570.15-$580.15 (recently defended), and immediate resistance at $611.85-$617.70. Technical consensus stands at “Buy”.

This technical configuration suggests that, with downside well supported and short-term momentum firming, Regeneron appears to be entering a structurally positive phase—timing that historically favours medium-term accumulation ahead of fundamental catalysts.

Fundamental Analysis

From a fundamental standpoint, Regeneron’s credentials remain formidable:

• Growth: Revenue growth remains robust, with Q4 2024 delivering a +10% year-on-year increase and full-year sales at $14.2 billion (+8%). The business continues to outperform peer averages in terms of scale and consistency.
• Profitability: The company posted a Q4 2024 net income of $918 million, with a diluted non-GAAP EPS of $12.07—a level that solidly underpins both its dividend and buyback initiatives.
• Valuation: Trading on a forward P/E of 15.41, Regeneron is currently valued at a tangible discount to its multi-year average and relative to large-cap biotech peers, particularly when adjusted for mid- to high-single-digit revenue growth and high operating margins.
• Balance Sheet Strength: A modest dividend yield (0.58%) and substantial cash flows provide meaningful downside protection and support further R&D and M&A.
• Innovation Leadership: Investments in R&D ($5.13 billion in 2024) and proprietary platforms (notably VelociSuite®) cement Regeneron’s role as an innovation leader, with unique advantages in antibody discovery, clinical trial efficiency, and IP protection.

Regeneron’s diversified revenue sources (immunology, oncology, ophthalmology) and expanding international presence add further resilience. The asset-rich pipeline (~40 clinical candidates), bolstered by recognised brand power (especially Dupixent and EYLEA), positions the company for sustainable outperformance.

Volume and Liquidity

Liquidity and trading dynamics remain highly favourable for Regeneron:

• Average volume: 1.13 million shares daily (3-month average) reflects deep institutional engagement, limiting spread volatility.
• Public float: At 104.06 million shares, float liquidity is sufficient to accommodate large orders without undue price disruption, supporting dynamic valuations and options-related strategies.
• Market capitalisation: At $65.36 billion, Regeneron commands blue-chip status, appealing to both growth and defensive investors.

Sustained, robust trading volumes around new technical lows further suggest growing market confidence, with long-term holders likely taking advantage of the recalibration to accumulate positions.

Catalysts and Positive Outlook

Looking forward, Regeneron’s investment thesis is reinforced by a succession of near- and medium-term catalysts:

• Product portfolio expansion: Recent FDA approvals for Dupixent (COPD, chronic spontaneous urticaria) open access to substantial new markets.
• M&A: The May 2025 acquisition of 23andMe ($256 million) bolsters Regeneron’s capabilities in genetic data analytics, accelerating precision medicine initiatives.
• Manufacturing scale: The $7 billion expansion with FUJIFILM Diosynth forms the backbone for future pipeline launches, lowering production risk and enhancing supply chain resilience.
• Clinical advancement: A pipeline of 40+ candidates in immunology, oncology, and ophthalmology offers regular milestones; BLA submission for linvoseltamab (decision due July 2025) is a notably high-impact event.
• ESG improvements: Doubling down on sustainable manufacturing and inclusive healthcare broadens institutional appeal, particularly among European ESG-focused funds.

Sectorally, the regulatory environment remains conducive to innovation, and global healthcare funding priorities are shifting markedly towards chronic disease and advanced therapies—areas where Regeneron holds deep expertise.

Investment Strategies

Regeneron’s current setup appeals to diverse investor profiles and time horizons:

• Short-term: The proximity to recent support levels ($570.15-$580.15) combined with potential post-catalyst volatility (notably the upcoming BLA decision) creates attractive tactical entry points for active traders.
• Medium-term: Investors may find value in participating ahead of new product launches and the full impact of recent acquisitions, leveraging the stabilising impact of dividends and buybacks.
• Long-term: The company’s formidable R&D engine, expanding geographical reach, and entrenched blockbuster franchises (Dupixent, EYLEA, Libtayo) favour multi-year compounders seeking core health exposure in the US market. For globally diversified portfolios—or Irish investors seeking US healthcare names less correlated with local benchmarks—current prices seem to justify renewed strategic interest.

Regeneron's relatively low beta (0.62) further supports inclusion for those seeking to diversify away from highly cyclical or rate-sensitive assets, underpinning steadier portfolio returns across cycles.

Is it the Right Time to Buy Regeneron?

In sum, the case for Regeneron stands on four robust pillars: (1) resilient and accelerating fundamentals, (2) compelling valuation with a discount to historic averages, (3) outstanding technical structure pointing to potential bullish reversal, and (4) a rich queue of catalysts and innovations ahead. Particularly at current price levels—near multi-year support and ahead of significant pipeline events—the stock seems to represent an excellent opportunity for both short- and long-term oriented investors seeking exposure to global healthcare innovation.

With analyst consensus coalescing around a $806 price target—offering +30% upside from current levels—and the business continuing to demonstrate adaptability, profitability, and innovation, Regeneron appears poised to enter a new bullish phase. For those with an optimistic view on biopharmaceutical advances and the appetite for resilient US growth, the fundamentals, technical dynamics, and sector outlook strongly justify renewed interest in the stock.

The coming months may well see Regeneron return to the vanguard of the biotech space—an opportunity that should be seriously considered for any forward-looking portfolio.

How to buy Regeneron stock in Ireland?

Buying Regeneron Pharmaceuticals (REGN) shares online is a simple and highly secure process for investors in Ireland, thanks to regulated brokers adhering to strict European standards. You have two principal methods to gain exposure: direct spot buying of shares (cash purchase), allowing you to become a partial owner, or trading via Contracts for Difference (CFDs), which lets you speculate on REGN's price movement with added leverage. The choice depends on your investing style and objectives. To help you find the best fit for your needs, you’ll find a detailed broker comparison further down the page.

Spot Buying

A cash purchase means you directly buy Regeneron shares on the NASDAQ, making you a shareholder and entitled to potential dividends. Irish-regulated brokers typically charge a fixed commission per order, often ranging from €4 to €10 (about $5–$11 USD), plus a small currency conversion fee if trading in USD.

Example

Suppose Regeneron’s share price is $605.39. With a $1,000 investment and a $5 brokerage fee, you can purchase approximately 1.64 shares ($1,000 - $5 = $995; $995 ÷ $605.39 ≈ 1.64 shares).

Gain scenario: If Regeneron’s price rises by 10% to $665.93, your shares are now worth $1,095.11 (1.64 × $665.93).

Result: Approx. +$100 gross gain (+10% on your investment), excluding currency and potential tax considerations.

Trading via CFD

CFD trading allows you to speculate on Regeneron's price movement without owning the underlying shares. CFDs are leveraged products typically offered by Irish and EU-regulated platforms. Costs include a spread (the broker’s markup on buy/sell prices) and, if you hold your position overnight, additional financing fees.

Example

With a $1,000 deposit and 5x leverage, you control a $5,000 position in Regeneron CFDs.

Gain scenario: If the stock price rises by 8%, you earn 8% × 5 = 40% profit on your investment.

Result: +$400 gain on your $1,000, before fees and charges are deducted.

Final Advice

Before investing in Regeneron, it’s essential to carefully compare brokers’ commission rates, spreads, platform features, and regulatory protections. Whether you choose to own the shares outright or trade flexibly via CFDs, your decision should align with your financial goals and risk appetite. For a detailed breakdown of the best brokers for Irish investors, see the comparator further down the page.

Our 7 tips for buying Regeneron stock

The latest news about Regeneron

Regeneron reported robust Q4 2024 results with revenues up 10% year-on-year, meeting analyst expectations. Driven by continued strong global demand for Dupixent and EYLEA HD, Regeneron's total Q4 sales reached $3.79 billion and annual 2024 revenues totaled $14.2 billion, an 8% increase over 2023. Net income for Q4 stood at $918 million, with earnings per share well aligned with consensus forecasts. This sustained commercial momentum is supported by stable prescription volumes in Europe, including Ireland, where both Dupixent and EYLEA are distributed and reimbursed under the HSE, maintaining Regeneron's important presence in the Irish pharmaceutical landscape.

Regeneron enhanced shareholder value through the initiation of a quarterly dividend and a major share buyback program. In February 2025, Regeneron introduced its first-ever quarterly cash dividend of $0.88 per share, signaling confidence in long-term cash generation and stability. Concurrently, the board approved an expanded share repurchase program up to $4.5 billion, reflecting robust balance sheet management. These actions are viewed favorably by institutional investors, many of whom, including Irish-based fund managers, emphasize total shareholder return in biotech allocations. The new dividend also makes REGN shares more attractive for Irish pension funds seeking high-quality international income names.

The recent acquisition of 23andMe for $256 million strengthens Regeneron's data and genetics capabilities for drug discovery. Finalized in May 2025, this fully confirmed and disclosed acquisition combines Regeneron's advanced VelociSuite® platform with one of the world’s largest genetic databases. The integration is expected to boost pipeline innovation and efficiency in drug development. For Irish healthcare and academic stakeholders, this implies future clinical collaborations and improved pharma R&D infrastructure, aligning with Ireland's established role as a European leader in biopharmaceutical research and production.

FDA approvals and expansion of flagship drugs signal ongoing growth opportunities for Regeneron’s European operations. Over the last year, regulatory milestones for Dupixent—now approved for both COPD (chronic obstructive pulmonary disease) and chronic spontaneous urticaria, including the April 2025 label expansion—have reinforced its blockbuster status. These approvals should drive further uptake across Europe and in Ireland, given the country’s rapid adoption of breakthrough therapies via the national health service and HSE reimbursement, consolidating REGN’s commercial footprint in the region.

Analyst sentiment remains strongly positive, with a consensus target price well above the current level amid technical buy signals. The average analyst price target is $806 versus a current price around $605, reflecting a potential near-term upside of over 30%. A broad base of research analysts (18 “Buy” out of 27) maintain a strong buy outlook, citing Regeneron’s resilient revenues, extensive pipeline of almost 40 clinical candidates, and successful product launches. Technical indicators show a favorable setup: moving averages for 20 and 50 days reflect buy signals, and the current price is situated above a solid support, attracting ongoing interest from European investors, including Irish professional asset managers, who are sensitive to global healthcare innovation and reliable growth.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.